GlassScriptPhysician profile
Janile Nelson
NPI 1588122386
$4,081.28
in general payments reported to CMS, 2019-2025
21 companies · $2,667 in 2025
The $2,667 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.63 · 2023: $43.63 · 2024: $1,340 · 2025: $2,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.88 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $532.80 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $424.65 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Axsome Therapeutics, INC. | $384.15 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $376.36 | 2024-2025 | Spravato |
| Alkermes, INC. | $328.21 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Corium, LLC | $302.13 | 2024-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $219.68 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $219.38 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $101.11 | 2025 | Rexulti |
| Tms Neurohealth Centers INC. | $74.58 | 2025 | Tms Neurohealth Centers INC. |
| Indivior INC. | $66.30 | 2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $54.66 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $52.38 | 2024-2025 | Quviviq, Quviviq |
| Almatica Pharma LLC | $49.52 | 2023-2024 | Loreev Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $46.55 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $43.03 | 2025 | Trintellix |
| Braeburn INC. | $35.68 | 2025 | Brixadi |
| Avanir Pharmaceuticals, INC. | $30.63 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.00 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $14.60 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janile Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.